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The immune system protects individuals against infections but can cause disease if the response 
is unbalanced. Immune responses include both innate and adaptive response, and these systems 
are connected. As the first line of defense, innate immune responses are immediately induced 
upon infection. In contrast, adaptive immune responses respond to antigens in a delayed but 
more specific and effective. The adaptive immune responses are classified into T-independent 
and T-dependent responses, and B cells play a vital role in antigen presentation and antibody 
production in both types of immune responses. Moreover, B cells are crucial in maintaining 
immune tolerance, and unregulated B cells may enhance autoimmune disorders.  This thesis 
focuses on B cell regulation in immune responses. 
Paper I identifies a novel interaction of scavenger receptor CD36 with LC3B regulating 
autophagosome generation in B cells in adaptive immune responses. CD36-deficient B cells 
exhibited a significantly reduced formation of plasma cells (PCs) and altered metabolism. These 
changes are accompanied by the impaired formation of autophagosomes. Autophagy induction 
led to colocalization of CD36 with autophagosome membrane protein LC3. Mice lacking CD36 
in B cells had reduced germinal center (GC) responses and autophagosomes in GC B cells in 
vivo.  
Paper II shows that B cell response to apoptotic cells (ACs) relies on endosomal pattern 
recognition receptors.  Syngeneic AC injections were used to break tolerance, and unc93b1 
mutant mice that lack signaling from the TLR3, TLR7, and TLR9 receptors were investigated. 
Autoantibodies against Ro-52/60, La, cardiolipin, and DNA were all lower in unc93b1 mutant 
mice. We also observed significantly less formation of GC B cells and follicular help T (Tfh) 
cells in unc93b1 mutant mice than WT mice.  
Paper III reveals a balance between conventional and unconventional Tfh cells direct 
autoreactive B cells. Coadministration of α-GalCer with ACs initiated follicular helper iNKT 
(iNKTfh) cell formation, which promoted short-lived GC B cells and IgG1 autoantibody 
production while restricted Tfh cells. We also observed that deletion of CD1d specifically in B 
cells limited early B cell activation, iNKTfh cell generation, GC B cell formation, and auto-
antibody production. Moreover, endosomal TLRs were required for iNKTfh cell-regulated GC 
response.  
In this thesis, we collectively evaluated the role of CD36, TLR3/7/9, and CD1d in regulating B 
cells in immune or autoimmune responses. It identifies critical players of CD36 in T-dependent 
 
 
immune response, TLR3/7/9 in autoimmunity, and iNKTfh cell-mediated help to autoreactive 
B cells. These studies contribute to our understanding of the connection between innate and 
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1.1 Overview of the immune system 
The immune system is responsible for preventing infection and keeping a balance in our bodies. 
To recognize and eliminate a diversity of microbes, humans have evolved an intricate network 
of cells that communicate and maintain immunity. The immune system needs to interact with 
others, such as the metabolic, nervous, and endocrine systems. Another requirement of the 
immune system is to maintain tolerance to self-proteins and nuclear acids. The absence of self-
tolerance will cause the immune system to attack our bodies leading to autoimmune diseases. 
From a historical perspective, the study of the immune system is driven by the human desire to 
survive infectious diseases. The earliest described observation of immunity was in 430 BC. 
Thucydides, the great historian of the Peloponnesian war, wrote that people who had survived 
through the plague could take care of the plague patients without contracting the disease. In the 
fifteenth century, the Chinese and Turks attempted to induce immunity. They used the dried 
crusts from the smallpox pustules to insert into minor cuts in the skin to prevent this disease[1]. 
In 1798, English physician Edward Jenner discovered that milkmaids infected with the mild 
disease cowpox had immunity to severe smallpox. The inoculating with cowpox that protected 
against smallpox spread quickly through Europe. Pasteur found microbes in this infectious 
disease and extended his discovery to other conditions, showing that attenuated microbes can 
be used as a vaccine to protect from infection. Subsequently, in 1885, Pasteur successfully 
developed the first attenuated vaccine for the rabies virus[2]. 
Although Pasteur showed that vaccination was effective, he did not understand the underlying 
mechanisms.  In 1890, the study showed that serum from vaccinated animals could protect 
others[3]. Another early observation done at the same time was when Elie Metchnikoff 
observed that phagocytes ingested microorganisms and other foreign material. In 1930, it was 
shown that a component from serum from an immunized individual named gamma globulin 
was required for immune activation by Elvin Kabat[4]. The immunologic events mediated by 
immunoglobulin were subsequently named humoral immunity. The immunity induced by 
specific cells was then called cell-mediated immunity. During an immune response, two 
systems called innate and adaptive immunity are interconnected and regulate each other. Innate 
immunity is the first defense line to prevent infections and quickly eliminates foreign antigens. 




including several epitopes on an individual antigen. It takes 5 or 6 days after the initial exposure 
to develop an adaptive immune response against a pathogen. The signals produced by the innate 
immune cause inflammation required for the adaptive immune response. An example of this is 
that adjuvants are needed for vaccination against a specific antigen.  
1.2 Lymphoid organs 
All blood cells develop from the hematopoietic stem cells (HSC) (Figure 1)[5, 6]. 
Hematopoiesis starts during embryonic development when precursor cells in the yolk sac 
differentiate into nucleated erythroid cells. Further, mature HSC is found in multiple tissues 
during embryogenesis, including the yolk sac, placenta, and fetal liver. These HSC can 
differentiate into both lymphoid cells and myeloid cells. The central lymphoid organ is where 
immune cells develop from HSCs through the myeloid and lymphoid pathways. The peripheral 
lymphoid organ is where naïve lymphocytes initiate the immune response. The central 
lymphoid organs are composed of bone marrow and thymus. The peripheral lymphoid organs 
Figure 1.  Illustration of the development of immune cells. All immune cells originate from hematopoietic 




comprise the spleen, lymph node, tonsils, Peyer’s patches, and mucosa-associated lymphoid 
tissue, where immune cells encounter antigens and induce the immune response.  
As the largest lymphoid organ, the spleen is a critical player in triggering immune responses 
against blood-borne antigens. Anatomically, the spleen can be divided into white and red pulp.  
Lymphoid follicles together form the white pulp.  A follicle is composed of surrounded a B cell 
zone and a T cell zone in the center required for the GC response against protein antigens. The 
marginal zone is localized on the edge of the white pulp, which connects the blood circulation. 
Marginal zones serve a critical role in capturing blood-borne microbes by phagocytes there[7]. 
Thus, the marginal zone contributes to initiating an adaptive immune response. The red pulp is 
on the outside of the white pulp marginal zones. Macrophages and DCs in the red pulp search 
for pathogens and clear up the damaged red blood cells. 
1.3 The innate immune system 
The innate immune system provides early and immediate protection against microbes and 
causes inflammation. Natural immunity displays in individuals even in a healthy status 
participate in the block and eliminate microbes from entering the host. The innate immune 
system includes physical barriers, chemical barriers, and cellular responses against infection. 
Physical barriers including skin, mucosal, and glandular tissue as the first defense line.  Our 
defense against infections also includes chemical barriers have anti-microbial substances, acid 
PH, complement proteins, and substances originating from granulocytic innate immune cells. 
The innate immune cells are mainly made up of myeloid cells such as DCs, monocytes, 
macrophages, granulocytes, and lymphoid cells, including natural killer (NK) cells and innate 
lymphoid cells (ILC). Myeloid cells can function as antigen-presenting cells during being 
stimulated to eliminate extracellular pathogens through phagocytosis or pinocytosis. Other 
specific receptors elicit the release of proteins and anti-microbial substances and cause swelling 
and other physiological changes that are part of inflammation. Pattern recognition receptors 
play essential roles in detecting pathogens and activating innate immune responses through 
recognition conserved through evolution. They appear on the cell surface but also 
intracellularly. Thus, evolution has provided us with pattern recognition receptors recognizing 
molecular patterns on pathogens that induce cell signaling activation. Besides, damage-
associated molecular patterns released by cells and tissue can be identified by these receptors.  
Examples of receptors on the cell surface are Toll-like receptors (TLRs), scavenger receptors, 




receptors and retinoic acid-inducible gene (RIG)-I-like receptors[8, 9]. TLRs were the first 
discovered pattern recognition receptors in the 1980s, and they are characterized by the shared 
protein structure of leucine-rich repeats. So far, 13 TLRs have been identified in humans and 
mice. Some TLRs on the cell surface recognize components on pathogens, while some 
endosomal TLRs recognize elements released during the degradation of microbes or as a 
consequence of necrosis[10]. Their cellular location enables them to respond optimally to 
recognize microbial ligands and self-antigens. The innate responses are sufficient to eliminate 
or at least control infections, and insects rely only on this system for their defense [11, 12]. For 
vertebrates, the natural and inflammatory response is often not enough to clear infections, and 
then the adaptive immune response comes to play and can also induce memory.   
1.3.1 Scavenger receptors 
Scavenger receptors are pattern recognition receptors displayed mainly on the cell surface. In 
1979, Drs. Brown and Golstein found that scavenger receptors could bind with modified low-
density lipoprotein, which defines the family. Many other ligands have been discovered since 
then, and the ligand-binding domain is a conserved cysteine-rich region. The scavenger receptor 
family includes lectin-like oxidized low-density lipoprotein receptor (LOX)-1, MACRO, and 
CD68, scavenger receptor class A (SRA), scavenger receptor class B (SRA), and others[13-16]. 
Scavenger receptors can recognize molecular patterns displayed on pathogens or infected cells 
such as lipoproteins, cholesterol ester, phospholipids. They can also identify modified self-
antigens, such as modified low-density lipoprotein and apoptotic cells. Scavenger receptors 
initiate innate immune responses, especially phagocytosis, to eliminate foreign antigens during 
the infection[17, 18]. 
The CD36 scavenger receptor belongs to the class B family and was first described by Paul A. 
Grimaldi in 1993[19]. CD36 has 472-amino acids and is a heavily glycosylated transmembrane 
protein. The extracellular region has a phosphorylation site at Thr92. Phosphorylation of CD36 
is critical for mediating adherence with other cells and binding ligands[20-22] and the 
interaction with lipid rafts to increase long-chain fatty acid uptake[23, 24]. CD36 is expressed 
by many cell types, including monocytes, lymphocytes, cardiac muscle cells, skeletal muscle 
cells, and adipocytes. The binding ligands include apoptotic cells, native or modified 
lipoproteins, glycated proteins, thrombospondin-1and long-chain fatty acids[25]. CD36 
contributes to recognizing pathogens, damaged tissues, and opsonin-independent pathogen 




role in cross-present antigens to CD8+ T cells.   CD36 is highly expressed by marginal zone B 
cells (MZBs) and low on FOBs on lymphocytes, and it has been shown to mediate T-
independent response to heat-killed Streptococcus pneumoniae[26]. CD36 can transport long-
chain fatty acid and oxLDL in adipocytes, enterocytes, muscle cells, and hepatocytes. Besides 
the immune system, CD36 expression in muscle tissue is associated with oxidative potential 
regulated by insulin[27, 28]. An essential function of CD36 on the cell surface is to enhance 
fatty acid uptake. In mice lacking CD36, the fatty acid uptake and binding of oxLDL were lower 
by peritoneal macrophages than WT mice[29]. CD36 serves a role in autophagy as well. Atg5-
deficient DCs have elevated CD36 expression and lipid accumulation[30]. The deletion of 
CD36 down-regulates CD5L-mediated autophagy and cytokine production in macrophages 
[31]. CD36 is also responsible for taking up long-chain fatty acid and oxLDL in adipocytes, 
enterocytes, muscle cells, and hepatocytes[32, 33]. 
1.3.2 Toll-like receptors 
The TLRs were first discovered in drosophila and essential for dorsoventral polarity in the 
embryonic stage[34, 35]. They are displayed on antigen presentation cells, including B cells, 
Figure 2. Toll-like receptor (TLR) signaling pathways. The figure exhibits the location and signaling 




DCs, and macrophages. The TLRs include TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, 
TLR8, TLR9, TLR10 expressed in both humans and mice, whereas TLR11, TLR12, and TLR13 
are only detected in mice (Figure 2)[36-38]. They are classified into subfamilies based on the 
similarity of amino acid sequences.  
As pattern recognition receptors in innate immune response, the TLRs bind with structurally 
conserved molecules derived from pathogens and lead to the activation of costimulatory signals 
and secretion of inflammatory cytokines. TLR1-6 and TLR10-12 are expressed on the cell 
surface and recognize microbes-derived molecules[39, 40]. Specifically, TLR4 on the surface 
is responsible for identifying lipopolysaccharide (LPS) in Gram-negative bacteria[41]. TLR3, 
TLR7, TLR8, TLR9, and TLR13 in mice are expressed in the endosomes, multivesicular 
bodies, endoplasmic reticulum, and lysosomes. They are responsible for identifying nucleic 
acids from both pathogen and damaged cells. TLR3 recognizes dsRNA and synthetic 
derivatives like polyinosinic-polycytidylic acid (poly I:C)[42]. TLR7 is specific for ssRNA 
analog-like resiquimod (R848)[43]. TLR9 is responsible for detecting bacterial DNA and 
synthetic analog CpG[44].       
The signaling pathway from TLRs is similar to the mammalian IL-1 pathway showing a 
connection between these receptors and cytokines necessary for inflammatory responses[45].  
Except for TLR3, all other TLRs rely on the MyD88 signaling pathway.  Ligand and leucine-
rich repeats in TLRs ectodomain trigger signaling through the alteration in the conformation 
and the association of the Toll/interleukin-1 receptor domains[46].  The connection between the 
Toll-interleukin receptor (TIR) domains and adaptor molecules is required for signaling. 
Mutations in MyD88 may cause selective influence on receptors [47], while certain MyD88 
TIR domains are responsible for the recruitment and activation of downstream signaling[48, 
49].  However, TLR3 signal through the adaptor adapter-inducing interferon-β (TRIF)[50]. 
TRIF connects with TNF receptor-associated factor 3 (TRAF 3) and TRAF6 and receptor-
interacting proteins 1 and 3. TRAF3 binds TANK-binding kinase 1 (TBK1) to the TRIF-
dependent pathway, which is associated with the inhibitor of nuclear factor kappa-B kinase 3 
(IKK3), phosphorylates, and activates interferon regulatory factor 3 (IRF3), causing IFNβ 
production[51, 52]. TLR4 signals through the same TRIF pathway, but it needs the TRIF-
related adaptor molecule under most situations.  
TLRs detecting host DNA can be involved in self-tolerance, and the interaction of self-DNA 
with endosomal TLRs is a possible trigger for autoimmune diseases. It has been shown that 




nuclear acid[53]. Moreover, the combination of activation of the BCR and endosomal TLRs 
enhances autoantibody production. Nucleic acid-sensing in other immune cells like DC can 
enhance autoreactive B cells[54]. After transcription, TLRs 3, 7, and 9 are coupled to membrane 
protein Unc93b1 to be transported from the endoplasmic reticulum to the endosomes to process 
and display antigens. Mice lacking Unc93b1 fail to initiate sufficient immune response 
preventing against auto-antigens[55, 56].  
1.3.3 Innate immune cells 
Innate myeloid cells include granulocytes, monocytes, and macrophages. Except for myeloid 
cells, lymphocytes such as NK cells and ILCs contribute to the natural immune response. 
1.3.3.1 Granulocytes 
Granulocytes respond rapidly during an innate immune response, and the cell types include 
neutrophils, eosinophils, basophils, and mast cells. All granulocytes have multilobed nuclei and 
are relatively large cells that distinguish them from lymphocytes. Granulocytes are also 
distinguishable by cytoplasmic granules that stain differently depending on content. These 
granules contain an extensive array of proteins and serve a vital role in the innate immune 
response as drivers of inflammation. Some enhance the remodeling of tissue in infection, and 
some directly eliminate pathogens.  
Neutrophils constitute about 50% to 70% of peripheral white blood cells and are the most 
numerous granulocytes. During infection, innate immune cells generate inflammatory 
molecules to promote the development of neutrophils from the bone marrow. The mature 
neutrophil migrates to the infection site and extravasates to the tissue. Here, they phagocytose 
bacteria and secrete various anti-microbial and tissue-remodeling proteins. Neutrophils can also 
regulate B cell responses by developing into B helper Neutrophils, and it has been shown that 
these can support a B cell response by the production of BAFF[57, 58]. Eosinophils can be 
stained a brilliant pink in standard H&E staining due to specific granules. Functionally, 
eosinophils are essential in defending against parasites, asthma, and allergy. They can also 
support PCs survival by producing the TNF family member APRIL. Basophils have large 
granules that stain blue in standard H&E staining. Basophils are a critical player in response to 
parasites, particularly helminths. In allergy, circulating antibody and antigen complex induces 
histamine release from their granules, which results in increased smooth muscle activity, 




Mast cells also play a vital role in defending against parasitic worms and cause allergies. All 
granulocytes can release cytokines that regulate other immune cells and initiate the adaptive 
immune response.   
1.3.3.2 Dendritic cells 
Dendritic cells (DCs) develop from monocytes that make up 2%-12% of leukocytes in the 
blood. Monocytes can differentiate into various mature cell types after migrating into specific 
tissues, where the two main ones are DC and macrophages. The close ontogeny between DC 
and macrophages is exemplified by Langerhans cells that reside in the skin. They were thought 
to be DC, but the finding that they develop from an embryonically derived macrophage stem 
cell in the tissue changed their classification[59]. The importance of this cell type for the 
immune response was highlighted when Ralph Steinman was granted the Nobel prize in 2011 
to discover DC in the mid-1970s.  
DCs functions as antigen-presenting cells and messengers between innate and adaptive 
immunity. Once they have encountered antigens, they take up antigens by pinocytosis and 
display them to major histocompatibility complex (MHC). Activated DCs can migrate and 
enhance antigen presentation and expression of costimulatory molecules. The mature DCs 
move to lymphoid organs and participate in antigen presentation. DCs can take up, process, and 
display extracellular antigens on MHC I and present to CD8+ T cells, called cross-presentation. 
It is critical in an immune response against viruses and tumors[60, 61]. Conventional DCs can 
be classified into CD8α+ cDC1 and CD11b+ cDC2[62]. 
1.3.3.3 Macrophages 
Some monocytes migrate into tissues in response to infection and differentiate into 
macrophages. The pro-inflammatory macrophages are essential in phagocytes and contribute 
to an effective innate immune response. By being activated by pathogens or tissue damage, they 
undergo phenotypical and functional changes and participate in the clearance of pathogens. It 
was recently shown that macrophages could also be originated from stem cells in the tissue that 
arise during embryonic development[63]. They are a very plastic population of cells, and cues 
from the tissue will determine their polarization and function.   
Recent studies found that surprisingly, most tissue-resident macrophages arise from embryonic 
cells instead of circulating monocytes. Tissue-resident macrophages include microglia in the 




self-renew. They co-exist with circulating macrophages and share their function as professional 
antigen-presenting cells. Macrophages are specialists for pattern recognition, and they also have 
Fc-receptors that can recognize immune complexes. Once a pathogen is coated with a specific 
antibody during an immune response, macrophages will bind to the immune complex, 
enhancing phagocytosis.  
1.3.3.4 Natural killer cells 
Nature killer cells were firstly discovered by Herberman et al. at the University of Pittsburgh 
and Rolf Kiessling, Hans Wigzell, and Eva Klein at Karolinska Institutet and in1975[64-67]. 
NK cells represent about 5%-10% of lymphocytes in blood and are defined by the expression 
of several surface markers, including NK1.1. They are part of the ILC family, belong to 
cytotoxic ILCs, distinct from helper-like ILCs like ILC1, ILC2, and ILC3[68]. They regulate 
the immune system via the production of cytokines and induce cytotoxicity to provide the first 
line of defense against the pathogens in the mucosal tissue and skin. They are also crucial for 
detecting tumor cells which is how they were discovered.   
NK cells release cytotoxic granules into extracellular space when encountering infected cells in 
infection. Besides this, stimulated NK cells can synthesize and produce the cytokine interferon-
γ (IFN-γ) to active macrophages[69]. Activated macrophages are more efficient in phagocyting 
microbes and secrete IL-12, IL-15, and type I IFN to enhance the ability of NK cells. Moreover, 
cytokine IL-15 from macrophages is vital in NK cell development, and IL-12 promotes the 
killing function[70, 71]. Collectively, NK cells and macrophages work together to prevent 
infection, especially for intracellular infection.  
NK cells kill infected cells and tumor cells via two distinct strategies. The first strategy is to 
attack cells that lack self-MHC class I molecules[72]. There is often downregulating MHC class 
I in the affected cells in tumor cells and infections induced by the virus. On the surface of NK 
cells, there are many receptors for self-MHC class I that limit the killing ability of NK cells. 
However, when NK cells encounter cells lacking MHC class I, the inhibiting receptors are no 
longer engaged, and NK can release their cytotoxic granule to kill the target cell[73, 74]. Since 
ligands of NKp46, NPG2D, NKp44, DNAM are highly expressed by infected and malignant 
cells, NK cells enable to mediate killing by specific ligation[75]. NK cells also express FcgRIII, 
which can bind to antibody complexes. It links the immune complex of antibodies and microbes 




cells release their granules and induce cell death. This process is called antibody-dependent cell 
cytotoxicity (ADCC). 
1.4 The adaptive immune system 
The adaptive immune system has an essential role in eliminating pathogens. Antigen-specific 
receptors on B cell and T cell are required for adaptive immune responses and make up the 
unique specificity. B cells and T cells are different in recognizing antigens. The BCRs are 
membrane-bound antibodies that bind 3D structures and can have an affinity for many types of 
molecules, such as proteins, lipids, nucleic acids, polysaccharides. B cell-regulated adaptive 
immune response protects against various microbes, soluble antigens, and cellular debris. T cell 
receptors are more restricted and recognize peptides from protein antigens bound to MHC on 
antigen presentation cells. Therefore, different antigens and epitopes on pathogens can be 
identified by B cells or T cells. Upon the antigen recognition, both B cell and T cells will be 
activated and differentiated into effector cells. Activated B cells can differentiate into GC B 
cells, PCs, or memory B cells. B cells can also produce cytokines regulating the immune 
response during their activation. During activation, different subsets of helper T cells derived 
from CD4+ T cells will be generated to control the adaptive immune response. The lymphoid 
blood cell lineage is broadly subdivided into populations based on phenotype and function. It 
includes T lymphocytes, B lymphocytes, unconventional T cells such as iNKT cells and type II 
NKT cells, and NK cells.   
1.4.1 T lymphocytes 
T lymphocytes acquire their name from their specific migration to the thymus, which is needed 
for their maturation. T lymphocytes originate from common lymphoid progenitors (CLP) and 
are essential in adaptive immunity. T cell receptor is the critical receptor used for their function 
and activation. In antigen presentation cells, MHC molecules form complexes with internalized 
proteins from the cell surface and present them to browsing T cells. There are two versions of 
MHC molecules called MHC I and II. MHC I is expressed by all nucleated cells, while MHC 
class II is only represented by antigen presentation cells. T cells can be classified into CD4+ 
helper T cells and CD8+ cytotoxic T cells based on the surface marker expression. Helper T 
cells recognize antigens displayed on MHC class II, whereas CD8 T cells identify antigens on 
MHC class I. DCs has the unique capacity to perform cross-presentation, which can present 




Upon the interaction of the MHC II-peptide complex, naïve CD4+ T cells become activated, 
expand, and divide into effector T-cells[76, 77]. Effector T-cells include helper T type 1 (Th1),   
Th2, Th17,  regulatory T cells (Treg), and Tfh cells. They have different functions in the immune 
response.  Helper T type 1 (Th1) cells are responsible for the immune response against ingested 
pathogens, while Th2 cells regulate our responses to parasite infections[78, 79]. Th17 cells 
contribute to the immune response against extracellular bacteria and fungi and regulate the 
intestine’s immunity. Each helper T cells secrete different cytokines that regulate the 
stimulation of B cell subsets, macrophages, DCs involved in the response. Another essential 
type of effector T cell is the Tregs that suppress the immune response mediated by helper T 
cells once microbes are eliminated. Tregs are characterized by the upregulation of CD4, CD25, 
and the transcription factor FoxP3 and regulate immune response to pathogens and stop 
reactions to self-antigens[80, 81]. Tfh cells provide help to activated B cells in GC response. 
They are essential in forming GC and providing signals to select the high affinity maturated 
and class-switched GC B cells and produce high-efficiency antibodies[82]. Cytokine IL-6 is 
required for switching from activated T cell to Tfh. Together with signaling from TCR and 
costimulatory molecules, these T cells will be induced the expression transcription factor Bcl-
6 and become Tfh cells[83]. Tfh cells are also defined by their excrete of IL-21 contributing to 
B cell differentiation.   
Naïve CD8+ T cells need to be activated to turn into cytotoxic T cells with the ability to kill 
other cells. It happens after interacting with MHC I peptide-complex and co-stimulation 
molecules on APCs. The cytotoxic T cells play an essential role in eliminating infected or 
altered cells. These cells include virus-infected cells, tumor cells, and cells recognized as 
foreign due to tissue transplantation. Although CD4+ T cells will not be directly engaged in the 
killing process, the provision of help from CD4+ T cells is required for the proliferation and 
differentiation of naïve CD8+ T cells.  
1.4.2 B lymphocytes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
In 1965, Robert Good and Max Cooper first found that cells from the Bursa Fabricius are 
required to produce antibodies. The B lymphocytes derive their name from these studies[84-
86]. B lymphocytes are distinguished from other cells by expressing B cell receptors, 
membrane-bound immunoglobulin molecule. B cell development starts at the bone marrow, 




In the immune response, antigen-specific responses largely depending on diverse receptor 
repertoires from which clones are selected to expand. Unlike pattern recognition receptors, BCR 
is recombined from separate gene segments in their correspondent gene loci, called variable 
diversity joining (VDJ) recombination. The immense diversity of genetic sequence results in 
the ability of BCRs to bind 1013-1018 different antigens[87-90]. V(D)J recombination occurs in 
the development of B in the bone marrow and thymus. The BCRs are composed of the subunits 
of receptors: Ig heavy and light chains; and α and β chains used for signaling.  Ig heavy chains 
of BCR include VDJ segments and light chains are made up of VJ segments. The recombination 
of VDJ segments is regulated by enzymes containing recombination activating genes (RAG) 1 
and 2, Artemi, and terminal deoxynucleotidyl transferase (TdT). Damaged DNA will be 
repaired by ligases, generating a recombined V-J or V-D-J exon with the help of RAG 1-2 and 
Artemis. TdT catalyzes the random nucleotides[91, 92]. Developing B cells create a diversity 
of repertoire receptors recognizing a wide variety of antigens.[93]. Self-reactive B cells are 
eliminated at bone marrow development stages to keep self-tolerance. This central tolerance 
also includes receptor revision where B cells can avoid self-reactivity by changing the light 
chain of the antibody. The exact mechanism for central tolerance for B cells is unknown and 
not as strict as T cell education in the thymus. After B cells leave the bone marrow, peripheral 
tolerance is mainly regulated by interactions with T cells, including Treg subsets.  
Upon receiving signals from the cell-surface receptors and adhesion molecules, B cells will be 
in the process of differentiation and proliferation, which promote their movement within the 
Figure 3. B cell development. The rearrangements at the gene segments of BCR lead to the formation of pre-B-
cell receptor, and is followed by a mature BCR that has antigen binding ability. After selection, non-self-reactive 
cells leave out the bone marrow, develop into transitional B cells, and become follicular B cells or marginal-zone 




bone marrow environment and form the immature B cells. Immature B cells leave the bone 
marrow and continue their further differentiation in second lymphoid organs. Besides antibody 
production, B cells play a vital role in cytokine production, antigen presentation, and immune 
memory. The predominantly function of mature B cells is to detect pathogens and differentiate 
them into PCs to produce antibodies to protect our body.  
 1.4.2.1 B cell subsets 
Once immature transitional 1 (T1) B cells leave the bone marrow, they migrate into the 
secondary lymphoid organs and become T2 B cells. T2 B cells phenotypically differ from T1 
B cells by IgD, CD21, CD23, and BAFF-receptor expression[94]. T2 B cells will turn into B-2 
B cells and become follicular B cells (FOBs) or MZBs[95, 96].  
FOBs in follicles are the predominant B cell subsets in the spleen and participate in T-dependent 
immune response[97]. Mature FOBs are characterized by high IgD and CD23 and intermediate 
expression of IgM and CD21. FOBs recirculate between lymphoid organs and blood to search 
for their antigen displayed by FDCs. They respond to encountered T-dependent antigens by 
BCR uptaking and presentation. As a result, B cells will undergo proliferation and 
differentiation during the immune response, including class-switching and differentiation to 
become PCs and memory cells[95]. Memory cells continue to recirculate and induce antibody 
response when they re-encounter their antigen.  
MZB cells get their name from their localization in the marginal zone at the edge of the white 
pulp. Like B-1 cells, MZB cells are capable of self-renew in the periphery and long-lived cells. 
They are characterized by the expression of CD21, IgM, CD36, CD9, CD1d, and relatively 
lower expression of CD23 and IgD[95, 96, 98]. CD21 functions as a receptor for the shuttling 
of antigens that have been opsonized to follicles for deposition on FDCs. The high expression 
of IgM and CD36 makes MZBs easier to activate and respond to antigens. MZB cells express 
phospholipid receptors and adhesion molecules needed to hold them in the marginal zone, and 
if these are blocked, MZBs go to the circulation[99, 100]. Also, the interaction between MZBs 
and marginal zone macrophages is essential for maintaining the MZ structure. MZBs can travel 
between the marginal zone and follicular to transport captured antigens into the follicles by 
accumulating antigens on FDCs [99, 101]. MZBs can also respond immediately to T-
independent antigens stimulation and become PCs[102].   
B-1 B cells are derived from the fetal liver, and most of them are located in peritoneal or pleural 




(about 2%) of the splenic B cells. B-1 B cells can be classified into B-1a (CD19hiCD5hi) and B-
1b cells (CD19hiCD5loCD11bhi), based on the expression of the CD5 and CD11b[95, 103]. The 
antibody repertoire of B-1a cells is selected to recognize lipid and polysaccharide antigens from 
both hosts and microbes. Although helper T cells can enhance antibody affinity by somatic 
hypermutation, B1-a B cells can produce antibodies in the absence of help from T cells. B1-a 
B cells perform a role that bridges innate and adaptive immunity to make antibodies. B-1 B 
cells differ from B-2 B cells based on phenotypes and function. 
Regulatory B cells (Bregs) are a subset of B cells contributing to immune suppression. Bregs 
include CD5+ B1a B cells, MZBs, T2-Mprecursor, and CD1dhighCD5+ B cells[104-106]. The 
suppression mechanism of Bregs is through the secretion of anti-inflammatory cytokine IL-10. 
Naïve B cells have no detectable IL-10 secretion, while stimulations of  BCR can induce the 
formation of Bregs, TLR, or CD40[107, 108]. It is also known that cytokines, such as IFN-γ, 
IL-6, IL-21, IL-33, and IL-1β, are required for their activation[109-112]. The regulatory 
function of Bregs was demonstrated in various models.   
1.4.2.2 B cell activation 
B cell subsets respond to both non-protein and protein antigens. Antigens can be classified as 
T-independent and T-dependent according to T cell help requirement. Nonprotein antigens 
initiate immune response primarily through T-independent responses. T-independent antigens 
can be divided into type I (e.g., lipopolysaccharide, bacterial DNA, CPG) and type II (for 
example, dextran, ficoll). T-independent type I response involves TLR but not BCR signaling. 
In contrast, T-independent type II response is mediated by the crosslinking of multiple BCRs 
and require signaling through Bruton’s tyrosine kinase (Btk). MZB responds quickly to 
nonprotein antigens in spleens, while B-1 cells in the peritoneum and mucosal tissues. The B1 
cells and MZBs are often considered innate-like B cells that express B cell receptors with 
restricted diversity and low affinity against microbes. At the same time, they can rapidly 
differentiate into short-lived memory cells and IgM+ PCs in the extrafollicular region[113].   
A critical step in the T-dependent response is when protein antigens are internalized by B cells 
via the BCR and presented on MHC II[114, 115]. When TCR recognizes the MHC II displayed 
epitopes, the CD3 and ζ chains transmit initiated signals. However, T cell activation requires 
co-stimulation of B cells as secondary signals[116-118]. B cells are activated by several 
signaling pathways[113]. Firstly, antigen-induced clustering of B cell receptors triggers signals 




tyrosine recruits Syk and downstream signaling cascades[119, 120]. B cells are also stimulated 
by other co-receptors such as CD19, CD21, and CD81 and pattern recognition receptors[120-
122]. CD21 is a receptor for C3b in the complement system that provides signals for the 
activation of opsonized antigens[121]. Immune response against T-dependent antigens will 
induce a GC response in follicles at the border to the T cell zone. FOBs and Tfh cells are the 
predominant cells recruited to this reaction. The same antigen-activated FOBs and made them 
migrate close to the T cells zone. For directing migration, activated T cells downregulate the 
level of chemokine receptor CCR7 on the surface. The expression of CXCR5 on cells in the 
follicle attracts them to B-cell zones[123, 124]. As has been mentioned, T cells express 
costimulatory molecules and secrete cytokines to help B cells[125, 126]. The best-characterized 
costimulatory molecule for T cells is two associated proteins CD80 and CD86 (named B7.1 and 
B7.2), recognized by protein CD28 on T cells[113, 116]. A co-receptor called ICOS (inducible 
costimulator) is connected to CD28 and is responsible for Tfh cell development in GC 
reaction[127]. Another important costimulatory molecule on T cells is the CD40 ligand, which 
binds to CD40 on B cells. After being fully matured by interacting with B cells, Tfh cells are 
characterized by expression of CXCR5, PD-1, CD40L, SAP, ICOS, Bcl-6, and secretion of IL-
21[125, 126].  
T-B cell interaction initiation results in GC formation with separated dark and light zones based 
on the histological appearance[128]. The combination of expression of CD83 or CD86 with 
chemokine receptor CXCR4 defines the light zone and dark zone GC B cells[129]. DZ B cells 
are characterized by CD83lowCXCR4high or CD86lowCXCR4high, whereas LZ B cells are 
CD83highCXCR4low or CD86highCXCR4low [129, 130]. B cell expansion is the most prominent 
feature of the dark zone that gets its name due to the dense cellularity of proliferating cells. The 
light zone is occupied by B cells undergoing clonal selection by interacting with Tfh cells 
(Figure 4)[93, 131]. Somatic hypermutations result in diverse BCRs, and the best clones are 
selected by Tfh cells[132]. Activation-induced deaminase (AID) frequently converts uracils to 
thymidines in the Ig variable region and induces the mutations[133]. The class-switching occurs 
in the Ig heavy chain constant region and is also driven by AID.  Activated B cells will 
differentiate into effector cells such as PCs and memory B cells. PCs continue to produce high-
affinity antibodies to eliminate the pathogen[134-136]. Memory B cells are ready for 
responding if they re-encounter the same antigen. And some of the memories of T-dependent 




1.3.2.3 B cell effector functions 
In the adaptive immune response, B lymphocytes recognize antigens to initiate a response and 
perform their roles. The most important function of B cells is antibody production. An antibody 
molecule comprises two identical heavy chains and light chains. Disulfide bridges connect these 
four chains to form a Y-shaped molecule[113]. A light chain contains a variable and a constant 
domain, and a heavy chain has a variable and three constant compartments. An antibody is 
composed of two antigen-binding sites in the variable regions. Functionally, antibody 
molecules can be divided into two identical Fab regions capable of binding antigens and one 
Fc region mediating effect function and biological activity. There are five distinct types heavy 
chain, μ, δ, γ, ε and α, which were identified based on the constant regions[113, 137]. 
Antibodies isotypes, including IgM, IgD, IgG, IgE, and IgA, are designated according to the 
heavy chains with different biological functions by binding to specific Fc-receptors.  
PCs produce antibodies and induce antibody-mediated effector functions. Antibodies enable to 
neutralize pathogens, enhance phagocytosis and activate the complement system. Moreover, 
antibodies can recruit and bind with cytotoxic CD8 T cells in an ADCC manner, like NK cells. 
Finally, anti-pathogen antibodies can trigger mediator release from the granulocytes through 
Figure 4 Somatic hypermutation selection of B cell in germinal center. High-affinity B cells clones get help 





degranulation. As B cells get activated and start the differentiation path to become PCs, they 
can also produce cytokine, such as IL-10.  
1.4.2.3 Autophagy in B cells 
When B cells get activated, they go through a program of differentiation that involves changes 
in metabolism and activation of autophagy. Autophagy is a metabolic process in cells that 
affects intracellular organelles and long-lived protein to produce energy and metabolic 
intermediates. Thus, it maintains cell survival during nutrients depletion. It can be divided into 
three classes: macroautophagy, microautophagy, and chaperone-mediated autophagy[138]. 
Macroautophagy is the predominant type and most studied. An extended cytosolic membrane 
encloses ubiquitinated cytosolic fragments to generate double-membrane vesicles called 
autophagosomes. These matured autophagosomes eventually fuse with lysosomes for 
autolysosomes which degrade the engulfed cellular compartment.  In microautophagy, the 
degradation happens in connection to the lysosomal membrane. During chaperone-mediated 
autophagy, cytoplasmic chaperones identify KFERQ motif promote induction of long-lived 
proteins[139-141]. The autophagy path can be divided into three different stages: initiation, 
elongation, and completion. Initiation of autophagosome requires the complex interplay 
between class III PI3 K and autophagy-related genes (Atg)[142, 143].  The extension engaged 
in ubiquitin-like conjugation, including Atg8/MAP-LC3/GABARAP/GATE-16 and Atg12. 
The phosphatidyl ethanolamine is then covalently be tied to a lipidated protein called LC3-II. 
Upon completion, LC3 keeps in the autophagosomal lumen, while Atg12–Atg5–Atg16 
complex will be cleaved off. The matured autophagosome combines with lysosome for protein 
degradation[144].  
Autophagy serves a critical role in B cell development. Mice lacking ATG5 in B cells fail to 
switch from pro‑ to pre-B cells in the bone marrow and maintain B‑1a B cells in the 
periphery[145]. Studies further demonstrate that autophagy is essential in B cell activation, PC 
formation, and humoral autoimmune responses[146, 147]. After BCR or CD40 in vitro 
activation, FOB cells switch from canonical to non-canonical, which mimics the GC response 
in vivo. The following transition of GC B cells into PCs involves returning to canonical 
autophagy. WD repeat domain phosphoinositide interacting 2 (WIPI2) is highly expressed in 
GC B cells and interested in this process. WIPI2 deficiency leads to impairment in the transition 




show that pattern recognition receptors drove autophagy to promote an immune response in 
preventing against microbes[149, 150].  
1.4.3 Invariant natural killer T cells  
iNKT cells are defined using Vα14Jα18 chains for TCRs in mice and part of the unconventional 
T cell pool. Just like other T cells, iNKT cells inhabit lymph nodes and spleens. They migrate 
to the follicular borders in lymph nodes and spleens to interact with antigen presentation cells 
during activation. As innate-like lymphocytes, iNKT cells recognize glycosphingolipid antigen 
presented by molecule CD1d. CD1d molecule looks like  MHC class I and is expressed by 
antigen presentation cells. There are five distinct CD1 molecules in humans, including CD1a, 
b, c, d, and e, while in mice, CD1d is the only lipid presentation molecule[151-153].   Instead 
of Vα14Jα18 chains for TCRs, type II NKT cells display more varying antigen receptors than 
iNKT cells and recognize hydrophobic antigens like sulfatide[154]. The glycosphingolipid α-
galactosylceramide (α-GalCer) is one of the most potent activation agonists for iNKT cells. 
iNKT cells and play a significant role in regulating and maintaining humoral immune responses 
when glycolipid antigens are presented. An example of this is that in iNKT cell-deficient Jα18-
/- mice, there is a failure to produce antibodies when the mice are immunized with antigen 
coupled to the glycolipid α-GalCer[155]. 
Signaling between iNKT cells and antigen presentation cells is mediated by molecules: CD1d-
TCR, CD40-CD40L, OX40-OC40L, and cytokines secretion: IL-2, IL-4, IL-17, IFN-γ, TNF-
α, etc. CD1d is expressed by B lymphocytes, macrophages, monocytes, and DCs[156]. CD1d 
internalizes lipid antigens and traffics them to endosome and lysosome. After activation, iNKT 
cells differentiate into effector cells and assemble as the function of Th1, Th2, Th17 cells, Tfh 
cells, and cytotoxicity T cells[157]. As innate-like lymphocytes, iNKT cells connect the innate 
and adaptive immune system and play a key role in anti-microbial, anti-tumor, and autoimmune 
responses. iNKT cells provide two different types of help to B cells, including cognate or 
noncognate help[158]. It relies on features of antigens co-immunized with α-GalCer.   
Immunization of α-GalCer targeted to B cells induces cognate iNKT cell help. Chemical 
haptens conjugated with αGalCer like NP-αGalCer are taken up and presented by B cells to 
produce antigen-specific antibodies[155, 159]. Also, α-GalCer alone can promote iNKTfh cell 
differentiation as a cognate help to B cells, an immature GC response, and antibody 




help and mediated via CD1d (Figure 5)[155, 158]. For example, transgenic MD4 B cells cannot 
elicit HEL-specific B cell proliferation in Jα18-/- mice after α-GalCer immunization[159]. 
After coadministration of protein antigens with α-GalCer, iNKT cells provide noncognate help 
to B cells and induce a long-lasting antibody response. After the immunization of α-GalCer 
together with protein antigens, iNKT cells are activated by DCs. The activated DCs will relocate 
to the edge of T and B zones. Protein antigens will be presented to MHC II, and internalized α-
GalCer will be displayed to CD1d. DCs provide activation signaling to both iNKT cells and T 
cells. The iNKT cells will differentiate into iNKTfh cells, which give a cognate helper to B 
cells[162, 163]. These B cells will proliferate and induce ligand expression for APRIL and 
activation factor BAFF, essential for the B cell response for long-term maintenance (Figure 
6)[158, 164]. Consequently, the noncognate immune response will promote the formation of 
GC, long-lived PCs, memory cells, antibody class switching, and affinity maturation.  
Figure 5. Cognate iNKT cell help for B-cell immune responses. For unassisted antigens, iNKT cells are in the 
provision of cognate help to B cells. αGalCer presented by CD8α+ DCs will induce iNKT cells activation and 
become iNKT FH cells. Through Ag-αGalCer complexes, the iNKT FH cells can provide help to B cell and result 




Moreover, costimulatory molecules CD80/CD86, CD40, and the production of IFNγ play an 
essential role in regulating the production of antibodies in cognate activation[155]. However, it 
has been shown that CD4+ T cells are dispensable for iNKTfh cells to provide cognate help to 
B cells[159]. Thus, in cognate help, the effector helper iNKT cells are dominated by iNKTfh 
cells alone[165]. iNKTfh cell is similar to the conventional Tfh cells largely for their phenotype 
and function[160]. Upregulation of transcription factor Bcl-6 and follicle-homing chemokine 
receptor CXCR5 is the crucial regulator for forming iNKTfh cells. Like Tfh cells, iNKTfh cells 
express PD-1, CD40L, and ICOS essential in B cell and iNKT cell interaction during an immune 
response[160, 166]. The cognate help to B cells from iNKTfh cells is also inhibited by SAP or 
CD28 depletion[160, 167]. iNKTfh cell differentiation also requires interaction with B cells 
similar to Tfh cells[160]. The expression of CD40 and CD1d is required on B cells to get 
cognate help from iNKTfh cells[160, 165]. iNKTfh cells contribute to form antigen-specific 
GC B cells and PCs[155, 160].   Furthermore, IL-4, IL-21, and IFN-γ secreted by iNKTfh cells 
are required iNKT cells and B cell interaction for their secretion[160, 168].  
Figure 6. Non-cognate iNKT cell help to B cells. Under the co-immunization of protein antigens with αGalCer, 
iNKT cells will be induced non-cognate help to B cells. Recognition of protein antigens by convential CD4+ Tfh 
cells lead to a typical TD immune response. The interaction of αGalCer-CD1d initiate iNKT cell activation. 




In the iNKTfh cell-mediated GC response, GC B cells will be generated, but they are not 
sustained and immature compared to the response supported by Tfh cells. Consequently, the 
response gives limited isotype switching, and antibodies dependent on iNKTfh cells also have 
a lower binding affinity. The PCs have a shorter half-life than Tfh mediated GC responses[160].  
It has been shown that α-GalCer activated iNKT cells are unresponsive to restimulation. 
Normally, B cells and T cells can recall memory to re-challenged antigens during adaptive 
immune responses. Unexpectedly, the iNKT cells fail to respond to re-challenged α-GalCer, 
probably due to a lack of proper co-stimulation.  After α-GalCer administration, there is the 
rapid loss of tetramer-positive iNKT cells due to downregulation of TCR that lasts about 
24h[169, 170]. Three days after injection, however, iNKT cells expand to the maximum. 
Subsequently, most iNKT cells undergo apoptosis and go back to steady-state numbers seven 
to ten-day after immunization[169, 171].  These iNKT cells become anergic for several 
months[172]. The unresponsive iNKT cells also do not produce IL-2 after re-stimulation, which 
is essential for iNKT cell expansion[172, 173]. The exogenous IL-2 stimulation breakthrough 
iNKT cells anergy bypass the TCR signaling. Anergic iNKT cells are impaired in killing cells 
in a melanoma model but can exhibit their effector functions in preventing autoimmune 
encephalomyelitis (EAE)[172].  
1.5 Autoimmune disease 
Although the immune system protects us against foreign antigens, it occasionally attacks our 
tissues resulting in autoimmune disease. Autoimmunity is predominantly mediated by 
autoreactive B cells and T cells and includes memory. Examples of autoimmune diseases 
include systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis 
(MS), inflammatory bowel disease (IBD), and type I diabetes.  
The immune system works coordinately to avoid an autoimmune response, and several 
mechanisms have evolved to achieve this. In the early development, central tolerance 
mechanisms in primary lymphoid organs for B cells and T cells are important. Central tolerance 
is achieved by eliminating self-reactive lymphocytes in the primary lymphoid organs during 
development. In central tolerance, elimination is often the first step in cell development. 
Through genetic rearrangement of DNA at the variable region and random nucleotides at the 
junctions, genetic diversity is induced in both B cell and T cell receptors[174]. Some variable 
regions will inevitably react with self-antigens. If all of them could develop into mature 




be eliminated in the bone marrow and thymus before their maturation[175, 176]. Lymphocytes 
with high-affinity TCRs and BCRs binding self-antigens will become anergic or apoptosis in 
primary lymphoid organs, and this process is called negative selection[177-179]. 
Although most immature lymphocytes with strong self-reactivity will be deleted in central 
lymphoid organs, some clones with weak self-reactivity can survive. Outside primary lymphoid 
organs, peripheral tolerance occurs and inhibits autoreactive lymphocytes. Peripheral tolerance 
is active and specific immunosuppression. For both B cells and T cells, it relies on immune 
cells with immune-inhibitory or regulatory function[180]. Treg cells are the most well-known 
in immune suppression, while subsets of B cells, DCs, macrophages, and myeloid-derived 
suppressor cells (MDSC) are also involved in regulation[179-182].  
Both CD4 and CD8 lymphocytes are regulated to avoid autoimmunity. Upon activation, TCRs 
on CD4 T cells will bind with antigens presented by MHC (signal 1). At the same time, T cells 
engage in the interaction between CD28 on T cells and CD80/CD86 on the antigen presentation 
cells (signal 2)[183]. CTLA-4 is also bound with CD80/CD86, inhibiting T cell activation, thus 
providing negative co-stimulation. The importance for this was shown in mice deficient for 
CTLA-4, which have enormous lymphocyte expansion and spontaneous autoimmune 
disease[184]. Activation of CD4+ Treg cells includes upregulation of the FoxP3 transcription 
factor, CTLA-4, and IL-2R α chain[185, 186]. People who inherited X-linked gene mutations 
in FoxP3 result in a multiorgan autoimmune illustrating the importance of this regulation [187]. 
It has been shown that CD4+ Treg cells play a critical role in graft rejection and also 
transplantation settings [188, 189]. Compared with CD4+ Treg cells, CD8+ Treg cells are less 
well characterized, less frequent, and described to have a more diverse phenotype[190]. Except 
for the expression of CTLA-4 and FoxP3, CD8+ Treg also highly express αα chains rather than 
α and β chains[191, 192].  The best-characterized CD8+ Treg cells are activated by nonclassical 
MHC I in humans and HLA-E Qa-1 mice[193, 194]. Adoptive transfer of CD8+ Treg cells 
protects mice from experimental autoimmune encephalomyelitis (EAE)[195, 196]. Treg cells 
reduce the costimulatory signals through surface molecules and cytokine secretion. An 
important mechanism is the downregulation of CD80/CD86 on the antigen presentation cells, 
possibly leading to immunosuppression by leveling the degree of activation[181]. 
Without T cell help (second signal), B cells become anergic and do not enter the GC if they re-
encounter their antigen. Therefore, the T-cell self-tolerance regulates peripheral tolerance of B-
cell as well[197]. Many experiments have also highlighted the importance of Bregs and the 




cell activation and a worsening of multiple sclerosis and rheumatoid arthritis[199, 200]. In 
humans, Bregs have been shown to be involved in disease activity of rheumatoid arthritis and 
lupus erythematosus[198, 201-203]. Another regulatory cell is the MDSC. They secrete 
inhibitory molecules like IL-10, arginase-1, inducible nitric oxide synthase (iNOS) and express 
the negative costimulatory molecule PD-L1 negatively modulate T-cells expansion[182].  
During the fetal and early neonatal stage, exposure to antigen results in suppression response 
as the immune system is set to become tolerant to the new environment[204]. Except for fetal 
exposure, factors that promote tolerance include exposure to large amounts of antigens, long-
time treatments with antigens, intravenous administration, absence of adjuvants, display of 
antigen by activated macrophages, DCs, and B cells. This is used in immune therapy of allergic 
individuals for treatment where the goal is to increase tolerance and reprogram the immune 
system.  
SLE is one of the most well-known examples of systemic autoimmune disease. Like many other 
autoimmune diseases, SLE is more common in females than males[205]. SLE symptoms 
typically appear at age 20-40 and are more prevalent in Hispanic and African Americans than 
other populations[206]. Genetic factors contribute to the occurrence of SLE as studies show 
that identical twins have a 60% risk of developing SLE if the other twin already was 
affected[207]. SLE patients suffer from type III hypersensitivity due to the formation of 
autoreactive immune complexes. These complexes initiate the complement cascade and form 
membrane-attack complexes that cause damage to blood vessels[208, 209]. In severe cases, 
large immune complexes can drive neutrophil accumulation and attachment to vascular 
endothelium and cause the spread of tissue damage[210]. SLE patients are diagnosed with anti-
nuclear antibodies or indirect immunofluorescence to stain autoreactive human cells. 
Several animal models have been used in SLE studies to provide insights into the genetic 
contribution to the disease. The most well-known spontaneous model is the F1 mice of New 
Zealand Black (NZB) crossed with New Zealand white (NZW). These mice produce 
autoantibodies and develop glomerulonephritis[211]. MRL/lpr mice are the other commonly 
used mice strain produced by hybridizing mice strains, including B6, C3H, AKR, and LG[212, 
213]. In MRL/lpr mouse, the Fas receptor gene mutation causes abnormal apoptosis in B cells 
and T cells[214, 215]. A population of double-negative T cells is generated in the mouse, which 
results in lymphadenopathy and splenomegaly[216, 217].  MRL/lpr mice produce 




Apart from spontaneous autoimmune models, induction models are commonly used in SLE 
studies. One of the well-characterized is the pristane-induced model. As a mineral oil, pristane 
injection induces SLE-related antibodies and lupus-like disease[221]. Resiquimod cream 
administered to the specific mice ears can also trigger SLE-associated disease after 
administration for 2-4 weeks. Due to the TLR7 ligand in the cream, the mice upregulate type I 
IFN and drive the condition [222, 223]. It is known that apoptotic cell clearance has a vital role 
in the SLE development in patients. Our studies employ a model with apoptotic cell injections 
to initiate SLE-like disease and break tolerance[224, 225]. The administered mice produce 
antibodies against ssDNA, cardiolipin, nuclear proteins and develop mild glomerulonephritis. 
A memory formed in the model where a boost administration can recall the immune response 
to apoptotic cells, and memory response is transferable to naïve mice[225]. Using this model in 
mice deficient in different tolerance checkpoints gives an enhanced disease. This model 
highlights that proper clearance of apoptotic cells is needed to avoid autoimmune disease.   
1.5.1 B cells in autoimmunity 
B cells play an essential role in modulating the pathogenic mechanism of autoimmune disease. 
Autoantibodies often are a driving force of autoimmune disease in patients[103, 226] [227]. A 
low level of autoantibodies can be detected in healthy individuals, suggesting that central and 
peripheral tolerance is not complete[228, 229]. A mild self-reactivity is required to maintain 
healthy and helps to clear cellular debris, whereas the self-reactive antibodies induce tissue 
damage during autoimmune disease. Thus, antibodies are generally sticky, a feature that is often 
described as being polyreactive.  
If B cell tolerance is broken and PCs are formed, they establish the autoimmune disease by 
producing switched autoreactive antibodies and generating memory. Shorted-lived PCs will be 
developed in the extrafollicular area, whereas long-lived PCs are created through GC 
responses[230]. PCs display various homing receptors based on the inflamed sites and migrate 
back to the infected sites[231, 232]. Here, inflammatory cytokines extend the lifetime of homed 
PCs and sustain antibody production[233, 234] [235]. PCs can be found with different 
phenotypes and various differentiation stages in autoimmune diseases. Some PCs can express 
CD20 and are then susceptible to rituximab treatment, where antibodies are used to deplete B 
cells[236, 237]. In contrast, some mature PCs migrated to the bone marrow do not express 




Autoreactive memory B cells will be generated in GC response during an infection. Some 
autoreactive memory B cells exhibit IgM expression, while a significant percentage switched 
to IgG or IgA. Human memory B cells upregulate the expression of CD27, which binds to CD70 
on T cells to help with their reactivation. The interaction enhances the transfer from memory B 
cells into functional PCs and strongly promotes antibody production even with a small degree 
of stimulation[239]. Autoreactive memory B cell formation is a crucial element in many 
autoimmune diseases and contributes to disease activity flares. However, memory B cells are 
sensitive to Rituximab treatment, depleting all memory B cells[240],[241]. 
1.5.2 B cell-directed immunotherapy  
Apart from Rituximab (anti-CD20), monoclonal antibodies against CD19, BAFF, CD22, and 
CD40 are used to treat autoimmune diseases.  
The expression of CD20 begins at the pro-B cell stage and increases in the maturation process. 
CD20 modulates B-cell activation, proliferation, and differentiation through the regulation of 
transmembrane Ca2+ [242]. Therefore, monoclonal antibodies against CD20 like Rituximab are 
efficient clinical therapy methods for autoimmune disease by inhibiting B cell activation[243].   
Of the other targets, CD19 is expressed on B cells, including pre-, immature, and mature B 
cells[244]. Therefore, CD19-direct therapies can also deplete early precursor, pre-, immature B 
cells mature B cells, peritoneal cavity B cells, pathogenic B cells, and inhibit humoral immune 
response[245, 246]. Like anti-CD20, CD19 mAb eliminates B cells via antibody-mediated 
cytotoxicity[245].  
Another way to target B cells is through the cytokine BAFF, secreted by DCs, macrophages, 
neutrophils, and Tfh cells.  This treatment is specific as BAFF receptors are mainly expressed 
by B cells. As a TNF family member, BAFF has a vital function in initiating the activation and 
preventing B cells from undergoing apoptosis. This is especially important during BCR 
ligation, where BAFF provides survival signals[247-249]. Thus, targeting BAFF has shown to 
be vital immunotherapy to suppress autoreactive B cells.  Clinical data show that belimumab, 
a BAFF antibody, results in B-cell depletion in SLE patients[250],[251]. It has been approved 
in the treatment of SLE in many countries.  
Finally, the costimulatory molecule CD40 is upregulated in B-cell development and provides a 
survival signal for B cells. CD40 ligand is predominantly expressed by CD4 T cells. In vitro, 




CD69 and CD154, elevates expression of CD80, CD86, MHC-II, CD95, and adhesion 
molecules VLA-4, and enhances the secretion of IL-6, TNF-α, and chemokines on B cell[252]. 
The interaction between CD40 and CD40 ligand enhances B cell activation, proliferation, and 
differentiation in the adaptive immune response. Humanized CD40 ligand and CD40 mAb used 
for treatment in targeting this pathway result in decreased serum level against double-strand 
DNA antibodies in SLE patients[253-255].  
1.5.2 Invariant nature killer T cells in autoimmunity 
iNKT cells induce immune responses against pathogens, but their role remains controversial in 
autoimmunity. Reduced iNKT cells in patients with autoimmune disease suggest that iNKT 
cells can have a protective role[256]. This is also consistent with other observations. Aging 
mice exhibit a deficiency of iNKT cells connected to autoimmune symptoms[257]. Mice 
deficient iNKT cells do not develop spontaneous autoimmune disease[256, 258].  
The different roles of iNKT cells in autoimmunity may be associated with different iNKT cell 
subsets and activation modes. When the inflammatory cytokine IL-18 is injected alone, iNKT 
cells block autoreactive B cell activation. This is mediated by interactions with neutrophils that 
license the NKT cells[259].  In contrast, if IL-18 is co-injected with glycolipid triggering 
iNKTfh cells, which enhance autoreactive GC response[161]. This could be the reason for α-
GalCer accelerated autoimmune in lupus mice models. In contrast to this, other studies show 
that the interaction of iNKT cells and Bregs inhibits the autoantibody responses[260-263]. 
Moreover, iNKT cells and CD1d inhibit autoreactive B cell activation in mice models using 
apoptotic cells induce autoimmune, which may also influence the formation of Bregs[264]. 
Collectively, iNKT cells are a double-edged sword in regulating autoreactive B cells, and the 











Paper I To investigate a possible role of scavenger receptor CD36 initiated autophagy in B cell 
regulated T-dependent humoral immune responses.  
Paper II To investigate the role of endosomal pattern recognition receptors in apoptotic cell 
mediated autoimmune response. 
Paper III To reveal the balance between conventional and unconventional follicular helper T 























3. RESULTS AND DISCUSSION 
3.1 CD36 and LC3B initiated autophagy in B cells modulates the humoral immune 
response (Paper I) 
Scavenger receptor CD36 plays an essential role in innate immune responses[26]. The role of 
CD36 has been described 
in macrophages but 
remains less explored in 
B cells. This study finds 
that CD36 mediated 
autophagy in B modulates 
T-dependent immune 
response.  
To study the role of CD36, we characterized the expression pattern of CD36 in different B cell 
subtypes. The highest expression was found in MZB and T2 MZP cells, followed by T1, GC, 
PC, IgM+ PC B cells (Figure 7). In vitro, the expression of CD36 in B cells was induced after 
stimulation with LPS, CPG, or anti-CD40+IL-4. The elevated CD36 level was found on the cell 
surface and intracellularly. We also show that B cells lacking CD36 formed fewer PCs than 
WT cells in ex vivo.  
Next, we screened mouse B cell lines to study 
the role of CD36 mechanistically and found 
that CD36 was highly expressed in CH12 
cells, a lymphoma cell line[265].  Using 
immunoprecipitation and mass spectrometry, 
we found that CD36 interaction proteins were 
involved in metabolism, and many of these 
were located in the endoplasmic reticulum 
and mitochondria. Depletion of CD36 in CH12 cells led to less formation of autophagosomes. 
After autophagy induction using rapamycin and chloroquine, CD36 was colocalized together 
with LC3B on autophagosomes. Co-immunoprecipitation was used to evaluate the 
colocalization of CD36 and LC3B. It showed that LC3B-II was co-immunoprecipitated with 
CD36 after the stimulation with rapamycin and chloroquine (Figure 8).  
Figure 7. CD36 staining in B cells from spleen of C57BL/6 mice. Taken 
from paper I.      
Figure 8. CD36 colocalized with LC3B under 




Given that CD36 was involved in forming PCs and in B cell autophagy, we performed 
additional in vivo experiments. It has been reported that CD36 deficiency mice produce fewer 
antibodies against Streptococcus pneumonia[26], but the role of CD36 in T-dependent antigen 
responses and contribution in different cell types remains unknown. To assess the role of CD36 
specifically in B cells, we crossed mice carrying floxed Cd36 alleles (Cd36fl/fl) with mice 
expressing Cd79a/Mb1Cre recombinase generating mice with specific deletion of CD36 in B 
cells[266, 267]. Sheep red blood cells (SRBCs) were used to immunize these mice as a model 
T-dependent antigen. The formation of GC B cells, Tfh cells, PCs, and antibodies were used to 
evaluate the immune response (Figure 9). In the GC response, we observed less formed GC B 
cells and Tfh cells in mice lacking CD36 in B cells. Mice with CD36-/- B cells also developed 
fewer overall PCs and class-switched PCs. The reduction of the formation of GC B cells and 
PCs also led to fewer antibodies against SRBCs in mice lacking CD36 B cells. We also 
confirmed the in vitro data and found that knockout mice had reduced the formation of 
autophagosomes in GC B cells. Using Cd36fl/fl Aicda-Cre mice[268], we showed that CD36 
expression in GC B cells partly contributed to the immune response to SRBCs. However, no 
difference was detectable between WT mice and mice lacking CD36 B cells after immunization 
with the T-independent type I antigen NP-LPS or the type II antigen NP-Ficoll. This shows that 
CD36 in B cells was required for T-dependent immune response and autophagosome formation. 
Collectively, this study reveals a novel role of CD36 in autophagy to support the GC response 
in T-dependent immune responses.  
 
Figure 9. Mice with CD36 depletion in B cell selectively impaired T-cell-dependent immune response. 




3.2 The B cell response to both protein and nucleic acid antigens displayed on apoptotic 
cells are dependent on endosomal pattern recognition receptors (Paper II) 
As pattern recognition receptors, TLRs serve a critical role in an innate immune response 
connected to infection. TLR3/7/9 receptors can sense DNA and ssRNA and are highly 
expressed by antigen presentation cells, including B cells, macrophages, and DCs.  Crossing 
TLR7 or TLR9 mice with MRL/Mplpr/lpr mice has demonstrated that TLR 7 and 9 were involved 
in the autoantibodies production[269]. However, it is unknown if these TLRs contribute to 
response against all autoantigens beyond DNA and RNA and related proteins. We used mice 
with a mutation in the Unc93b1 (3d) gene that lacks the function of TLR3/7/9. We know from 
previous studies that consecutive immunization with apoptotic cells initiates SLE-like 
phenotype without severe pathology. Thus, we immunized 3d mice and WT mice with ACs 
weekly four times to induce an autoimmune response. We found that autoantibodies were 
produced against both nucleic acids, including DNA, histone, SmD1, Ro-52, Ro-60, La, and 
unrelated antigens like Cardiolipin Phosphoryl Choline. To identify an even broader spectrum 
of autoantibodies, we used an autoantigen array with 128 autoantigens. No difference between 




WT and 3d mice was observed without immunization in background levels of antibodies in 
serum. However, after injection, the data shows that autoreactive IgG against nuclear, 
circulating, membrane and cytoplasmic antigens were diminished in 3d mice compared to WT 
mice. This was true for both IgM and IgG antibodies showing that depletion of endosomal TLRs 
reduced all types of reactivities (Figure 10). The formation of PCs is mediated through 
extrafollicular and follicular GC responses. Short-lived IgM-producing PCs are predominantly 
found by extrafollicular responses, while the long-lived and class-switched are preferentially 
from GC responses[270]. We measured IgM and IgG antibody responses at different time points 
to investigate the kinetics and role of endosomal TLRs. Apoptotic cell injections led to elevated 
autoantibodies against DNA, cardiolipin, and other autoantigens. The 3d mice had reduced 
production of autoantibodies and GC formation. The reduction in GC formation was 
accompanied by decreased Tfh cells in the 3d mice. Next, PC responses and effects on class-
switching were assessed. After injections, we found decreased IgM+, IgG1+, IgG2+, IgG3+ PCs 
in the 3d mice compared with WT mice. We also investigated the generation of age-associated 
B cells (ABCs) that arise in old humans and mice and chronic inflammation. They have been 
shown to contribute to autoimmune disease and are defined by the expression of transcription 
factor T-bet and surface marker CD11c[271]. We found that in the 3d mice, there was also a 
reduction in the formation of ABCs compared to WT mice.  Thus, we conclude that both auto-
antibody responses and generation of B cell phenotypes connected to chronic inflammation 
were dependent on endosomal TLR signaling.  
 Endosomal TLRs are expressed by both DCs and B cells and could contribute to the activation 
of these and other cell types in this model[272]. To understand the intrinsic role in B cells, we 
made mixed BM chimeras generated by a 1:1 mixture of WT (CD45.1): WT (CD45.2) or WT 
(CD45.1): 3 d (CD45.2) bone marrow. Two months after transplantation, the mice were injected 
with apoptotic cells as in previous experiments, and immune responses were evaluated. The 
differentiation into GC B cells and PCs from 3d (CD45.2) was 2-fold lower than that of the 
CD45.1 allotype. This shows that GC B cells and PCs from 3 d mice cells expanded less and 
were not as activated compared to WT cells. No difference between WT and 3 d bone was 
detected for the reconstitution of B1 cells, MZBs, FOBs, and T cells. The data shows that TLRs 
deficiency, specifically in B cells, drives the phenotype. We assessed signaling differences 
between WT and 3d mice B cells after F(ab)2 anti-IgM induction. We found that BCR-induced 
calcium signaling was comparable between wild-type and 3d B cells. Moreover, to show the 




with LPS.  No difference was found between WT and 3 d mice in cell proliferation and 
apoptosis. Collectively, endosomal TLRs deficiency mice respond comparably as WT mice to 
BCR and TLR4 stimulation, suggesting that the cells developed normally. The phenotype was 
directly connected to the response induced by apoptotic cells. In summary, the data shows that 
TLR3/7/9 are essential in self-tolerance and serve as a critical link between innate immunity to 
autoimmunity.  
3.3 The balance between convention and unconventional follicular helper T cells direct 
autoreactive B cells (Paper III) 
iNKT cells induce a quick immune response to foreign and self-antigens and can have a dual 
function in regulating B cell responses. How iNKTfh cells contribute to autoimmune response 
is poorly characterized. Here, we investigate this in the apoptotic cell model induced break of 
B cell tolerance and use the iNKT cells agonist α-Galcer to shift the function of iNKT cells 
from regulators to helpers. Mice were injected with vehicle or ACs alone four times or AC+α-
GalCer for the last two injections. Co-injection activated both iNKTfh and Tfh cells, but both 
populations were minor than α-GalCer alone or AC alone (Figure 11). As proof of activation 
increased, Bcl-6 and CD40L were expressed by iNKTfh cells relative to CXCR5-PD-1- iNKT 
cells. To investigate how this balance between iNKTfh and Tfh cells affected the response, we 
examined GC B cells and PCs formation. We found that mice immunized with AC+α-GalCer 
formed more GCs B cells than ACs alone, and they were located in the follicles. Thus, the 
combined activation of iNKTfh and Tfh gave a more robust response than AC alone. Also, 
coadministration elicited less PC and IgG1+ PC than ACs alone, confirmed by 
immunofluorescence. For long-term response, mice were injected with ACs five times, again 
Figure 11 Immunization with α-GalCer triggers the generation of iNKTfh cells. Representative contour 




with the addition of a-GalCer for the two last injections, and spleens and serum were collected 
14 days after the last injection. Like with the shorter regime, we observed that mice with ACs+ 
α-GalCer formed fewer GC, IgG1+ GC B cells, and autoreactive IgG1 compared with ACs 
alone. Next, to investigate whether CD1d on B cells are required in the response, mice carrying 
floxed Cd1d alleles (Cd1dfl/fl) were crossed with mice with Cre-recombinase under the control 
of Mb1 promotor (Mb1-Cre) and produced mice (Cd1dfl/flMb1Cre) that deletes Cd1d 
specifically in B cells. The glycolipid α-GalCer alone was injected into the mice to investigate 
cognate iNKT cell help, and as expected, we found that Cd1dfl/flMb1Cre mice had less B cell 
activation. The mice lacking CD1d on B cells also resulted in immature GC response and fewer 
IgG1+ GC B cells. Of importance, we also found fewer iNKTfh cells in mice lacking CD1d on 
B cells, and the ones generated were immature based on less PD-1 expression. Moreover, mice 
bearing CD1d-/- B cells had less total and Ig class-switched PC than WT mice. Thus, CD1d 
expression on B cells was needed maturation of iNKTfh cells and antibody production. To 
characterize iNKTfh cells mediated help to B cells, we immunized Cd1dfl/fl and Cd1dfl/flMb1-
Cre mice with AC+α-GalCer. Mice lacking CD1d on B cells formed fewer GC B cells than WT 
mice. Tfh cell formation was comparable between WT and KO mice, while the iNKTfh cell 
formation was impaired in mice lacking CD1d on B cells. Further, mice lacking CD1d in B 
cells led to fewer IgM+, IgG1+, and IgG3+ plasmablasts. Autoreactive IgG1 against autoantigens 
from mice bearing CD1d-/- B cells was significantly lower than WT mice. Collectively, mice 
without CD1d on B cells initiate less iNKTfh cells mediated GC response and autoantibody 
production. Finally, to assess the role of endosomal TLRs in iNKTfh cells trigged GC response, 
we used unc93b mice with deficiency for endosomal TLR3/7/ 9. The data showed that unc93b 
mice had less GC B and iNKTfh cell generation than WT mice, while Tfh cell activation was 
comparable. In summary, iNKTfh cells promote autoreactive B cell formation, and CD1d on B 










4. CONCLUSION AND FUTURE PERSPECTIVES 
The balance provided by the immune system has evolved to maintain integrity and health. 
Abnormal regulation in the immune system can trigger diseases like uncontrolled infection, 
autoimmune, and cancer. B cells exhibit a critical function in the immune response, including 
antigen recognition and presentation, immune cell activation, GC response, and production of 
antibodies. It is essential to know the molecules contributing to B cell function and regulation 
to restore immune balance. This thesis investigates the role of CD36, endosomal TLRs, and 
glycolipid presenting molecule CD1d in B cells in the immune response. The significant 
findings and future perspectives of the thesis are the following: 
I. CD36 and LC3B initiated autophagy in B cells regulates the humoral immune response  
Paper I reveals that the scavenger receptor CD36 in B cells regulates T-dependent immune 
response through autophagy. Depletion CD36 in B cells shows defects in forming total and 
class-switched PCs in vitro.  CD36 function was associated with intracellular metabolism, 
including mitochondria, endoplasmic reticulum, cytosolic part, etc. CD36 deficiency B cells 
led to less autophagosome formation than WT B cells. And we also found that CD36 was 
colocalized and interacted with LC3 under autophagy induction.  Mice without CD36 
expression impaired the response to type II T-independent antigens[26]. Using mice 
conditionally deleted for CD36 in the B cell compartment, we demonstrated that functional 
CD36 in B cells is required for GC response. These results are significant as they describe a 
new function for this pattern recognition receptor in B cells. In the future, it will be interesting 
to investigate if this is also true for other scavenger receptor family members. Also, human B 
cell lymphoma can express CD36, and it would be interesting to examine if CD36 plays a role 
in the survival and adaption of these cancer cells.   
II. The B cell response to both protein and nucleic acid antigens displayed on apoptotic cells is 
dependent on endosomal pattern recognition receptors  
Paper II reveals that endosomal TLRs regulates autoreactive B cells in autoimmunity. B cell 
can take up nucleic acids through BCR internalization for endosomal activation of TLRs 3, 7, 
and 9. The engagement results in a signaling cascade initiation and induces a second signal to 
activated B cells. Mice that lack endosomal TLRs still generate B1 cells, MZBs, and FOBs. 
However, they fail to active GC B cell response and form class-switched PCs. The failure of 




illustrates the importance of TLRs in autoimmunity and their potential role in immunotherapy. 
In line with paper I, this is excellent proof to show the connection of innate and adaptive 
immune response by regulating pattern recognition receptors to B cells. Future studies are 
warranted to uncover the mechanism of endosomal TLRs mediated autoimmunity. 
Additionally, mice lacking endosomal TLRs, specifically in B cells or DCs, will be needed to 
clarify the cell-specific roles. An important finding is that all auto-antigen specificities are 
dependent on endosomal TLRs. Thus, targeting these could be used for targeted treatments and 
block all autoantibodies classes. 
III. The balance between convention and unconventional follicular helper T cells direct 
autoreactive B cells 
Paper III investigates how iNKT cells regulate autoimmunity when differentiated into iNKTfh 
cells. Immunization with AC+α-GalCer resulted in quick increasing GC B cells and iNKTfh 
cells and autoantibodies. The results suggest that iNKTfh cells modulated the early GC and 
autoimmune response and impacted the long-term response. After coadministration, we found 
a balance in T cell help where fewer iNKTfh cells were generated than α-GalCer alone and 
fewer conventional Tfh cells than AC alone. Thus, the data shows the competition between 
iNKTfh cells and conventional Tfh cells upon coadministration. We also found that CD1d on B 
cells was needed to mature the iNKTfh cells fully and form GC response and autoantibodies. 
The endosomal TLRs in mice were also required for iNKTfh cells regulated GC response. 
Future studies are warranted to uncover the exact mechanism that results in the competition 
between iNKTfh cells and Tfh cells and the iNKT cells mediated B cell activation. Several 
reports investigate the balance between different Tfh populations, and this study shows that 
activation of unconventional T cell help will direct and modulate the Tfh response. Hopefully, 
these findings will lead to studies on balance between different types of helper T cells and 
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